The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors
BCL-2抑制剂维奈托克(VEN)和FLT3抑制剂吉瑞替尼(GIL)的多药联合疗法在急性髓系白血病细胞中的活性高于新型多药BCL-2/FLT3 VEN-GIL混合单分子抑制剂。
期刊:European Journal of Medicinal Chemistry
影响因子:5.9
doi:10.1016/j.ejmech.2024.117190
Goodis, Christopher C; Eberly, Christian; Chan, Alexandria M; Kim, MinJung; Lowe, Brandon D; Civin, Curt I; Fletcher, Steven